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1. Introduction 
One of the most pronounced effects of Thyroid Hormone (TH, Triiodothyronine (T3), 
Tetraiodothyronine (T4)) is modulation of metabolic efficiency, energy expenditure and 
calorigenesis. Thus, hypothyroidism results in decreased energy expenditure and basal 
metabolic rate  accompanied by weight gain and cold intolerance, while hyperthyroidism 
results in hypermetabolism,    weight loss despite increased energy intake, intolerance to 
heat, loss of lean mass,  bone resorption and tachycardia. TH role in modulating metabolic 
efficiency has been realized for over a century but its cellular mode-of-action remained to be 
resolved.  
2. Mode-of-action of TH in modulating metabolic efficiency 
The first description of TH-induced calorigenesis dates to 1895 (1). That initial report has 
been followed by exhaustive data focusing on the phenomenology of TH action as reflected 
by hyper- and hypothyroidsm. Thus, high levels of TH in mammals increase oxygen 
consumption and heat production, resulting in pronounced body weight loss, while low 
levels of TH are associated with a decrease in  metabolic rate and the oxidation of energy 
substrates (glucose, fatty acids and amino acids), resulting in pronounced increase in body 
weight  (2-6). Although it was widely accepted that TH stimulates calorigenesis by affecting 
respiration, its cellular mode-of-action remained to be resolved. Hence, exhaustive attempts 
were made by the scientific community throughout the twentieth century to verify the 
mechanism(s) involved in modulating metabolic efficiency by TH. Studies by Lardy and 
Feldott (7) and Hess and Martius (8) have pointed out during the 1950s, that the respiratory 
control ratio of  isolated mitochondria was robustly decreased in the presence of added T4. 
TH was thus claimed to have direct action at the mitochondrial level by inducing 
‘mitochondrial uncoupling’, namely, dissociating mitochondrial phosphorylation from its 
substrate oxidation driver.  However, the high T4 doses used in those studies implied 
possible non-physiological activity rather than authentic TH-induced calorigenesis.  Later 
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evidence in support of ‘mitochondrial uncoupling’ has however  indicated  increase in 
oxygen consumption and mitochondrial proton permeability of isolated liver mitochondria 
derived from hyperthyroid rats,  with concomitant  decrease in   mitochondrial phosphate 
potential and inner mitochondrial membrane (IMM) potential (9, 10).  These observations 
were further corroborated by increase in liver oxidizing capacity of hyperthyroid rats  
accompanied by decrease in  phosphate and  cytosolic redox potential (11), while opposite 
effects were reported in livers of hypothyroid rats (12).  Similarly, hepatocytes isolated from 
T3-treated rats show higher oxygen consumption and lower IMM potential as compared 
with non-treated control (13-16).  Also, a decrease in IMM potential has been reported in 
TH-treated human lymphocytes or those derived from hyperthyroid patients (17).   Overall, 
these findings suggested that TH indeed induces mitochondrial uncoupling, and that 
mitochondrial uncoupling may account for the cellular mode-of-action of TH in modulating 
metabolic efficiency in vivo. 
Concomitantly with the proposed mitochondrial paradigm of TH, others have proposed 
non-mitochondrial activity of TH in modulating metabolic efficiency. Thus, TH was claimed 
to induce “futile substrate cycles”, namely, opposing energy-requiring metabolic pathways 
that proceed simultaneously without generating net products, e.g. glycolysis accompanied 
by gluconeogenesis, lipolysis with lipogenesis (18, 19),  Na+/K+ ATPase with concomitant 
Na+/K+ leakage (13),  or  glycerol-3- phosphate/NADH mitochondrial shuttling (20).  
However, these proposed mechanisms could account for only a small fraction (about 15%) 
of the total increase in oxygen consumption induced by TH (13, 21), resulting in a 
mitochondrial paradigm consensus for TH-induced calorigenesis. Yet, the concerned 
mitochondrial targets still remained enigmatic. 
3. Nuclear / mitochondrial targets of TH 
TH effects in the mitochondrial context may consist of long-term effects that are dependent 
upon gene expression, and short-term effects that are refractory to inhibitors of protein 
synthesis.  An important finding reported by Tata et al (2), indicated that the calorigenic 
activity of TH was abrogated by actinomycin D, implying that TH-induced mitochondrial 
uncoupling is mediated by modulating nuclear gene expression of respective mitochondrial 
and/or extra-mitochondrial proteins. These results were followed by extensive studies ((22, 
23) and others) that resulted in discovering the nuclear TH receptors (THR) of the 
superfamily of nuclear receptors, acting as target for TH in modulating nuclear gene 
expression. THR are encoded by two distinct tissue-dependent genes coding for splice 
variants of the THRbrain, bone, heart) and THRliver, brain, heart) isoforms. THR 
homodimers or heterodimers with other members of the superfamily of nuclear receptors 
(e.g., retinoic X receptor (RXR)) may interact with TH-response elements (TRE) in the 
promoters of TH-responsive genes, resulting in transcriptional activation or suppression as 
function of transcriptional co-activators or co-suppressors recruited by TH/THR to the 
transcriptional complex of respective promoters.  Indeed, TH binding to nuclear THR results 
in direct transcriptional activation of the expression of genes coding for components of 
mitochondrial oxidative phosphorylation (i.e. βF1-adenosine triphosphatase, adenine 
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nucleotide translocase (ANT), cytochrome c1) (24, 25), or genes coding for intermediate 
factors that are indirectly involved in promoting the nuclear expression of mitochondrial 
components (i.e. nuclear respiratory factors 1 and -2, peroxisome proliferator-activated 
receptor-γ coactivator-1) (26), or in stimulating mitochondrial DNA replication (27). Hence, 
TH-induced mitochondrial uncoupling was believed to be accounted for by TH-induced 
gene expression of respective protein targets that modulate mitochondrial oxidative 
phosphorylation. In pursuing putative proteins involved in TH-induced mitochondrial 
uncoupling, a number of candidates have been suggested. These included the adenine 
nucleotide translocase, proteins that are involved in phosphatidylglycerol and cardiolipin 
synthesis (28), and in particular the mitochondrial uncoupling proteins (UCPs). 
4. Mitochondrial uncoupling proteins (UCPs) 
With the discovery of UCPs, extensive efforts were invested in verifying their putative role in 
mediating the calorigenic effect of TH. In fact, the UCP-coding genes have TREs in their 
promoters and their expression level is increased by TH treatment, implying their putative role 
in mediating TH-induced calorigenesis (40). UCP1 (29) mediates proton leak in brown adipose 
tissue IMM (30), resulting in uncoupling fuel oxidation  from ATP synthesis  and in dissipating 
IMM potential as heat. The adaptive thermogenic response of UCP1 is driven by the 
sympathetic nervous system in response to cold temperature or high-energy cafeteria diet, and 
could apparently serve as target for TH in modulating total body energy expenditure. Indeed, 
recent findings by Lopez et al (31) have indicated that TH treatment results in suppressing 
hypothalamic AMP-activated protein kinase (AMPK) activity, resulting in SNS-induced 
thermogenic response of brown adipose fat. However, UCP1 is specifically expressed in 
brown adipose tissue, which is sparse in adult humans. While recent findings point to some 
brown adipose islets in adult humans (32-37), their putative impact on total body energy 
expenditure still remains to be resolved.  Hence, other proteins that share sequence homology 
with UCP1(38), including the ubiquitously expressed UCP2,  and in particular the UCP3 that is 
expressed in skeletal muscle, were pursued for their role in mediating TH-induced 
calorigenesis (39). However, the following observations may indicate that  UCP2 and UCP3 
may not account for TH-induced mitochondrial uncoupling (41).  Thus, findings suggest that 
UCP2/3  do not contribute to adaptive thermogenesis (42), but may have a role in ROS 
signaling (43) and/or in exporting fatty acid anions from the mitochondrial matrix (44). Also, 
the expression of liver UCP2/3 proteins is restricted to Kupffer cells, implying that the 
uncoupling effect of TH in liver parenchymal cells is not due to UCPs. Most importantly, 
UCP3 knock-out mice are lean and show normal response to TH (45), leaving unresolved the 
specific proteins that may mediate TH metabolic effects in the mitochondrial context.  
5. Mitochondrial permeability transition pore (PTP)  
In analogy to UCPs, mitochondria consist of Permeability Transition Pores (PTP) (46-50) 
located at the contact sites of the inner (IMM) and outer (OMM) mitochondrial membranes. 
The molecular composition and structure of mitochondrial PTP still remains to be resolved. 
The current model of PTP consists of the integral proteins ANT (in the IMM), the voltage-
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dependent anion channel (VDAC, in the OMM), cyclophylin D (CypD, in the mitochondrial 
matrix) and the Bcl2 family of proteins (in the OMM). PTP gating may present itself in 
definitive or transient modes, differing in reversibility and synchronization (51, 52). 
Definitive synchronized PTP gating is induced by intramitochondrial Ca+2 load (53),  and is 
enhanced by oxidative stress, depletion of adenine nucleotides, increased inorganic 
phosphate, increased matrix pH, and depolarization of the IMM (54-56). This 
opening/gating mode results in high-conductance PTP (HC-PTP), extensive depolarization 
of the IMM (~70% decrease in IMM potential), rapid passage of ions and solutes of less than 
1500 Da across the IMM, and mitochondrial swelling. These may lead to rupture of the 
OMM, release of mitochondrial proapoptotic proteins (such as cytochrome c, apoptotic 
intrinsic factor), followed by programmed cell death/apoptosis (57).  Alternatively, 
spontaneous, non-synchronized, transient/flickering  PTP gating due to cyclic opening and 
closure of individual PTP channels may result in reversible and limited depolarization of the 
IMM (~30% decrease in IMM potential), moderate decrease in proton motive force, and 
passage of solutes of less than 300 Da, accompanied by mitochondrial contraction rather 
than swelling (58-63). Most importantly, in contrast to the irreversible proapoptotic 
depolarization inflicted by definitive PTP gating, transient low conductance PTP (LC-PTP) 
gating is innocuous and reversible, leading to mild mitochondrial uncoupling. These 
findings may indicate that LC-PTP may serve as mitochondrial target of TH in inducing 
physiological mitochondrial uncoupling and calorigenesis.   
6. Mitochondrial PTP gating by TH 
In testing the role played by PTP gating in TH action, a straightforward approach would be to 
examine whether TH-induced uncoupling is inhibited by the PTP specific inhibitor, 
cyclosporin A (CSA).  CSA acts as a potent inhibitor of PTP gating due to its binding to CypD, 
resulting in interfering with CypD interaction with PTP-ANT (64, 65). Indeed, TH-induced 
lowering of mitochondrial membrane potential and proton gradient followed by 
mitochondrial swelling are all eliminated by added CSA, pointing to PTP involvement in TH 
mitochondrial activity (66, 67). In addition, liver mitochondria of hypothyroid rats show  
decrease  in mitochondrial Ca+2  efflux, swelling and protein release, being restored by TH 
treatment (68-70). Furthermore, TH treatment of Jurkat cells induces induce LC-PTP gating 
(71), implying that mitochondrial PTP may serve as target for TH in inducing mitochondrial 
uncoupling. However, as described below, TH activity in gating PTP is not accounted for by 
modulating gene expression of structural components of mitochondrial PTP.  
Adenine Nucleotide Translocase (ANT): ANT is a central player in oxidative 
phosphorylation due to its primary function in translocating adenine-nucleotides via the IMM. 
ANT function in the PTP context  has been verified by its direct association with CypD and 
VDAC (72), as well as by PTP gating being activated and inhibited by the ANT ligands 
Atractylate and Bongrekic acid, respectively (73). Moreover, ANT/CypD/VDAC- reconstituted 
liposomes show PTP characteristics in terms of sensitivity to Ca+2,  CSA and ANT ligands ((74, 
75) but see also (76)).  Also, over-expression of ANT isoforms (ANT1, ANT3) promotes 
apoptosis, being inhibited by CSA (77, 78). Moreover, ANT expression levels affect 
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mitochondrial IMM potential, with high ANT levels resulting in IMM depolarization and 
mitochondrial proton leak (71, 77, 79). Hence, in light of ANT structural and  regulatory 
functions in the PTP context, and  since  the expression level of ANT2, the only ANT isoform 
expressed in liver, is increased in hyperthyroidism  and decreased  by hypothyroidism (80), 
TH-induced ANT expression could apparently account for liver TH-induced LC-PTP gating. 
However, over-expression of ANT2 in HeLa cell line or in rat primary hepatocytes resulted in 
extensive mitochondrial depolarization that was not inhibited by CSA (71), implying  the 
formation of PTP-nonrelated ANT channels (81), or of CSA-insensitive PTP (82).  Lack of an 
obligatory linkage between PTP and ANT conforms to other findings pointing to PTP gating 
by proapoptotic ligands in liver cells or isolated mitochondria that lack ANT (76).  
Cyclophilin D (CypD): CypD is a member of the family of peptidyl-prolyl cis-trans 
isomerases (PPIase) (83). The CypD protein contains a mitochondrial-targeting sequence 
that directs it specifically to the mitochondrial matrix. The link between CypD and PTP has 
been verified by CypD direct association with ANT (72) as well as by CSA inhibition of PTP 
gating due to its interaction and inhibition of  CypD activity (64, 65, 84). Moreover, PTP 
opening by Ca+2  and oxidative stress was enhanced in isolated mitochondria of neurons 
over-expressing CypD (85), while CSA-sensitive PTP opening was abrogated in isolated 
mitochondria of CypD knock-out mice (86). These CypD characteristics may indicate that 
CypD could apparently serve as protein target of TH in inducing PTP opening and 
mitochondrial uncoupling. Indeed, liver mitochondria of hyperthyroid rats show increased 
expression of CypD as well as its PPIase enzymatic activity (71), while opposite effects 
prevailed in liver mitochondria isolated from hypothyroid rats.  However, over-expression 
of CypD in HeLa cell line, or in rat primary hepatocytes, resulted in mitochondrial 
hyperpolarization rather than PTP opening (71, 87). Moreover, over-expressed CypD was 
found to desensitize cells to apoptotic stimuli or to protect cells from mitochondrial 
depolarization and apoptosis induced by over-expression of ANT1 (77, 78). Hence, TH-
induced CypD expression may not account for TH-induced PTP gating and calorigenesis.  
CypD  induction by TH may reflect TH activity in inducing peptidyl-prolyl cis-trans 
isomerase activity and protein folding rather than PTP opening (88). 
Voltage Dependent Anion Channel (VDAC): VDAC is a highly abundant protein of the 
OMM. Its primary function consists of  exchanging anions between the cytosol and the inter-
membrane mitochondrial space (89). Previous findings have indicated its putative role in 
gating mitochondrial PTP (90-94). However, its expression level  is  not changed by in vivo 
TH treatment (71), excluding VDAC from being a molecular target of TH in inducing 
mitochondrial uncoupling. 
7. Modulation of Bcl2-family proteins by TH 
The family of Bcl2 proteins consists of more than 20 proteins that were extensively studied 
in terms of their role in cell death (95). The Bcl2 family is grouped into two main 
subfamilies: proapoptotic proteins (e.g. Bax, Bak, and others) and anti-apoptotic proteins 
(e.g. Bcl2), which promote or inhibit PTP gating, respectively (95-97). Bcl2-family proteins 
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may directly interact with PTP components such as ANT (98-100) or VDAC (101), and when 
over-expressed or added to isolated mitochondria  may specifically induce (e.g. Bax and 
Bak) (102-104) or antagonize (e.g. Bcl2) (105) PTP gating. Similarly, depletion of 
proapoptotic Bax or Bak results in failure of PTP gating (98, 105, 106), whereas Bcl2 
inactivation results in definitive PTP gating triggered by oxidative stress (107). Thus, 
mitochondrial Bcl2-family proteins and their respective heterodimers (e.g., Bax/Bcl2, 
Bad/Bcl2) may apparently serve as candidate targets of TH in inducing mitochondrial 
uncoupling (108-110). Indeed, TH-induced PTP gating is accompanied by increase in 
mitochondrial Bax and Bak, together with decrease in mitochondrial Bcl2 content, whereas 
hypothyroidism results in opposite effects that are reversed by TH (71). Modulation of the 
mitochondrial content of Bcl2 proteins by TH is due to their specific translocation in/out of 
mitochondria, rather than reflecting modulation of their expression and total cellular 
content.  Amplifying the ratio of mitochondrial pro- vs. anti-apoptotic proteins, results in 
robust decrease in mitochondrial Bax/Bcl2 heterodimer with concomitant increase in free 
Bax, leading to PTP gating by free mitochondrial Bax (111). Indeed, over-expression of Bcl2 
protects against TH-induced mitochondrial PTP gating (71), implying that depletion of 
mitochondrial Bcl2 by TH may account for TH-induced mitochondrial uncoupling.  
8. Extra-mitochondrial upstream signals that induce TH-induced  
PTP gating mediated by Bcl2-family proteins 
Since Bcl2-Bax hetrodimerization may depend on Bcl2(S70) phosphorylation state (112), 
mitochondrial Bcl2 depletion by T3 was further verified in terms of Bcl2(S70) 
phosphorylation profile. Indeed, concomitantly with decrease in mitochondrial Bcl2, T3 
treatment results in decreased phosphorylation of monomeric mitochondrial Bcl2(S70) as 
well as of Bcl2(S70)-Bax heterodimer (113), indicating that mitochondrial Bcl2 depletion may 
reflect Bcl2(S70) dephosphorylation by TH. In pursuing kinases (e.g. PKA, PKC) or 
phosphatases (e.g. PP2A, PP2B/Calcineurin) reported to be involved in Bcl2(S70) 
phosphorylation (112, 114), neither PKA, PKC nor PP2A were found to mediate 
phosphorylation/dephosphorylation of Bcl2(S70) by TH (113). In contrast, 
dephosphorylation of Bcl2(S70) and the depletion of mitochondrial Bcl2 protein by T3 are 
both reversed by the FK506 inhibitor of PP2B, indicating that the TH effect may  be 
mediated by activation of PP2B (113). Furthermore, added FK506 blocksT3-induced opening 
of PTP, indicating that dephosphorylation of Bcl2(S70) and its mitochondrial depletion by 
T3-activated PP2B may account for mitochondrial PTP opening by TH.  Since TH-induced 
PP2B activation was not accompanied by increase in PP2B expression, PP2B activation  was 
further pursued by searching for TH-induced increase in cytosolic Ca+2 (113).  Indeed, Ca+2 -
activated PP2B has previously been reported to bind and dephosphorylate Bcl2(S70)  (115, 
116). Most importantly, T3 treatment resulted in pronounced increase in Ca+2, while Ca+2  
chelation by BAPTA resulted in abrogating LC-PTP gating by TH, indicating that TH-
induced PP2B activity  involved mobilization of intracellular Ca+2 (113). Indeed, T3-induced 
mobilization of intracellular Ca+2  has recently been reported to mediate a variety of non-
genomic effects of TH (117, 118).      
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The dynamic equilibrium between cytosolic Ca+2 ([Ca+2]c) and endoplasmic reticulum (ER) 
Ca+2 ([Ca+2]ER) is maintained by an interplay between the inositol 1,4,5-trisphosphate 
receptor (IP3R1) and the sarcoplasmic Ca+2 ATPase (SERCA) that catalyzes  ER Ca+2 efflux 
and influx, respectively (119).  IP3R1 is activated by binding of the IP3 ligand and may 
further be modulated by its phosphorylation by PKA, PKC or CaMKII, its 
dephosphorylation by PP2B, or by its association with one or more of about 50 proteins, 
including FKBP12 or Bcl2 (120, 121). The putative role played by IP3R1 in TH-induced PTP 
gating was evaluated by verifying the effect of TH in cells lacking IP3R1 (113). Thus, PTP 
opening, dephosphorylation of mitochondrial Bcl2(S70) and depletion of mitochondrial Bcl2 
are all abrogated in cells lacking IP3R1, indicating that IP3R1 is indeed required for TH-
induced mitochondrial uncoupling.  Similarly, T3 is ineffective in increasing [Ca+2]c upon 
inhibition of IP3R1 by 2APB, indicating a specific requirement for IP3R1 activity in 
modulating [Ca+2]c by TH. Furthermore, T3-induced gating of IP3R1 is accounted for by 
both, increase in IP3R1 expression and protein levels, complemented by IP3R1 truncation 
into channel-only isoforms.  Truncated IP3R1 isoforms have been reported to serve as  
channel-only peptides capable of carrying out [Ca+2]ER efflux in the absence of  added IP3 
(122-126). IP3R1 truncation by TH may reflect TH activation of IP3R1 proteases that remain 
to be further verified. The  IP3R1 / PP2B crosstalk in mediating TH-induced PTP gating is 
supported by  constitutive PP2B-induced PTP gating  under conditions of suppressing 
IP3R1 expression by siRNA (127). Hence, PP2B is acting downstream to TH-induced IP3R1, 
and is obligatory as well as sufficient in mediating PTP by [Ca+2]c.   
Over all,  TH-induced expression of the IP3R1 channel accompanied by its truncation is 
proposed to result in [Ca+2]ER efflux, increase in [Ca+2]c and  [Ca+2]c-activated PP2B, 
followed by dephosphorylation of mitochondrial Bcl2(S70) with concomitant decrease in 
mitochondrial Bcl2 protein levels and increase in mitochondrial free Bax (Scheme 1). The 
decrease in mitochondrial Bcl2 and/or the respective increase in mitochondrial free Bax 
may initiate and promote variable PTP gating, resulting in physiological LC-PTP–
induced calorigenesis. LC-PTP gating may drift to HC-PTP–induced apoptosis as 
function of additional prevailing conditions that may affect mitochondrial permeability 
transition.    
9. Thyromimetic agents and energy expenditure     
Increase in energy expenditure by TH has long been considered for treating obesity.  Indeed, 
treating obesity by thyroid extracts was quite popular throughout the 20th century and well 
into the 1970s, being later abandoned due to severe side effects consisting of cardiac 
dysrhythmias, bone resorption / osteoporosis, electrolyte disturbances, and loss of lean body 
mass (128). Thus, a final ruling warning against the use of thyroid preparations for the 
treatment of obesity of euthyroid subjects has been issued by the FDA on 1978.  Similarly to 
TH, treating obesity by uncoupling of mitochondrial oxidative phosphorylation by 2,4-
dinitrophenol (DNP) has been introduced on 1933, but  abandoned on 1938 due to fatal 
hyperthermia (129). 
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Scheme 1. PTP-induced calorigenesis by Thyroid Hormone and MEDICA Analogs 
These early attempts were followed by rational drug design of  synthetic structural analogs 
of TH that may  avoid  the  lethal chronotropic cardiac effects of TH, while maintaining the 
beneficial effects of TH in the context of diseases of the Metabolic Syndrome (130, 131). Most 
efforts in that direction were invested in designing thyromimetics that selectively target the 
liver TH-receptor isoforms (THR) while avoiding the heart isoforms (THR). Tissue 
selectivity has been further pursued by designing thyromimetics that undergo selective 
hepatic uptake. These efforts have mainly resulted in thyromimetics effective in treating 
dyslipidemia, due to increased expression of hepatic LDL-receptors together with CYP7A1 / 
7-alpha-cholesterol hydroxylase, resulting in enhancing hepatic uptake of LDL-cholesterol 
and its conversion into bile. Liver-specific thyromimetics were further found to induce the 
expression of the hepatic scavenger receptor SR-B1 that mediates reverse cholesterol 
transport.  However, in contrast to the advances made in designing hypolipidemic 
thyromimetics, the efficacy of thyromimetics in treating obesity and obesity-induced 
diabetes type 2 still remains to be verified. Moreover,  the use of thyromimetics for treating 
diseases of the Metabolic Syndrome involves potential harmful risks due to:   a. The partial 
selectivity of  thyromimetics for hepatic THR, resulting in positive chronotropic effects as 
well as enhanced bone and muscle catabolism induced by high-dose. Hence, the safety of 
hypolipidemic thyromimetics still remains to be verified in subjects suffering from 
congestive heart failure or coronary heart disease. b. Since THR regulates the feedback loop 
Increased mitochondrial Bax
PTP opening
Mitochondrial uncoupling
Whole body energy expenditure, weight loss
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of hypothalamic TSH, thyromimetics may suppress the production of endogenous TH, 
resulting in combined hypo- and hyperthyroidsm. These limitations, combined with our 
present view of the mode-of-action of TH in the mitochondrial context, may however point 
to an alternative strategy, namely synthesizing thyromimetics that may directly target 
mitochondrial PTP while avoiding the TH/THR transduction pathway altogether.  
Long chain fatty acids (LCFA) have long been shown to induce mitochondrial uncoupling 
due to   their protonophoric activity (81, 132) and/or PTP gating ((51, 133), and ref therein), 
implying a potential mitochondrial thyromimetic activity. However, the uncoupling activity 
of LCFA is confounded by their dual role as putative uncouplers of oxidative 
phosphorylation and as substrates for oxidation or esterification. MEDICA analogs consist 
of long chain dioic acids (HOOC-C(α′)-C(β′)-(CH2)n-C(β)-C(α)-COOH (n=10-14)) that are 
substituted in the αα′ or ββ′ carbons (134). MEDICA analogs may be thioesterified 
endogenously into their respective mono acyl-CoA thioesters (135), however, they are not 
esterified into lipids nor β-oxidized, thus dissociating between the substrate role and the 
putative uncoupling activity of natural LCFA. 
Similarly to TH, MEDICA analogs induce calorigenesis in animal models in vivo. Thus, 
treatment of   rats with MEDICA analogs results in an increase in oxygen consumption 
accompanied by a decrease in liver mitochondrial phosphate potential and cytosolic redox 
potential, reflecting mitochondrial uncoupling in vivo (136). Furthermore, treatment of obese 
leptin receptor-deficient rats (e.g. Zucker, cp/cp) with MEDICA analogs results in increased 
oxygen consumption and food consumption together with weight loss, implying increased 
total body energy expenditure (137, 138). Also, the non-protonophoric mitochondrial 
activity of MEDICA analogs is similar to that of TH (71), in terms of promoting CSA-
sensitive decrease in phosphate and redox potentials with concomitant increase in oxygen 
consumption in cultured cells as well as in vivo (11, 16, 67, 139, 140), indicating that both 
MEDICA analogs and TH do converge onto LC/HC-PTP gating  (11, 71).  Indeed, similarly 
to TH, PTP gating by MEDICA analogs is mediated by modulating the profile of 
mitochondrial Bcl2-family proteins, resulting in decrease in mitochondrial Bcl2-Bax 
heterodimer with concomitant  increase in mitochondrial free Bax (71, 113). However, 
different transduction pathways are involved in modulating the mitochondrial content of 
free Bax by TH or MEDICA analogs.  Thus, dissociation of the Bcl2-Bax heterodimer by TH 
is driven by dephosphorylation of Bcl2(Ser-70) by T3-activated PP2B (113), whereas 
dissociation of the Bcl2/Bax heterodimer by MEDICA analogs is driven by 
dephosphorylation of Bad(Ser-112, Ser-155) (141). The decrease in phosphorylated Bad(Ser-
112, Ser-155) results in its decreased binding to14-3-3 followed by its increased binding to 
mitochondrial Bcl2, resulting in Bax displacement and PTP gating (142, 143). Decrease in 
phosphorylated Bad by MEDICA analogs is due  to  suppression of the Raf1/MAPK/RSK1 
and the adenylate cyclase/PKA transduction pathways, and their respective downstream 
targets Bad(Ser-112) and Bad(Ser-155) (141). Hence, the TH and MEDICA transduction 
pathways converge at their downstream Bax target but diverge upstream of the Bcl2/Bax 
heterodimer (Scheme 1).  LC-PTP gating by MEDICA analogs may account for their 
thyromimetic calorigenic activity in vivo. 
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10. Conclusion 
Energy expenditure by TH has long been realized to be accounted for by uncoupling of 
mitochondrial oxidative phosphorylation. However, the mode-of-action of TH in promoting 
mitochondrial uncoupling remained elusive. Mitochondrial uncoupling by TH is transduced 
by TH-induced gating of mitochondrial PTP due to modulating its Bcl2-family proteins.  
This mode-of-action underscores the physiological aspects of mitochondrial PTP in 
modulating metabolic rate, in contrast to most previous studies that analyzed mitochondrial 
PTP in its apoptotic context. TH-induced gating of mitochondrial PTP may offer a whole 
new dimension of developing novel anti-obesity drugs that promote weight loss by 
targeting mitochondrial PTP. 
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